60 mn Americans now eligible for Pfizer booster shots, Biden says
POOL / AFP)

US President Joe Biden(C), alongside Antony Blinken(L) United States Secretary of State, and John Kerry, US Special Presidential Envoy for Climate, leaves after addressing the 76th Session of the UN General Assembly on September 21, 2021 in New York. - US President Joe Biden told the United Nations General Assembly on Tuesday that America is "opening a new era of relentless diplomacy" following the end of the war in Afghanistan. (Photo by John Minchillo / POOL / AFP)

International |
3 m read

60 mn Americans now eligible for Pfizer booster shots, Biden says

AFP
By AFP
|
Washington, United States By Lucie AUBOURG
Some 60 million people in the United States are now eligible for a Pfizer booster shot against Covid-19, President Joe Biden said on Friday as a regulatory marathon laying bare divisions within the scientific community on the issue came to a close. In the end, US health authorities have recommended boosters for three categories of people: those 65 and older, those 18-64 with an underlying medical condition such as diabetes or obesity, and those who are especially exposed to the virus because of their work or where they live. The at-risk group is large and includes teachers, grocery store employees, health care workers, prisoners and people living in homeless shelters. A total of 20 million people got their second Pfizer shot long enough ago -- at least six months -- to qualify now for a booster, Biden said. "Go get the booster," he said in remarks at the White House. "I'll be getting my booster shot," the 78-year-old president added, "as soon as I can." Biden said people who have received Moderna or Johnson & Johnson vaccinations could get booster shots once studies have been completed and he expected that all Americans would be eligible "in the near term." Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), said Friday that data on Moderna and Johnson & Johnson booster shots would be evaluated "in the coming weeks." Some immunocompromised people in the United States have been eligible to receive a third dose of the Pfizer or Moderna vaccine since early August. Biden had wanted to launch a mass campaign of Pfizer and Moderna booster shots this week for all Americans. But the move was put on hold by the US health authorities. Moderna did not submit the necessary data in time and experts were divided about what to do regarding Pfizer. The CDC on Friday overruled its own panel of health experts to back Pfizer booster shots for individuals at high risk of exposure to Covid-19 because of their jobs.  

- 'The greatest good' -

  Walensky said the agency had to act on "complex, often imperfect data" for the greater good of public health. "In a pandemic, even with uncertainty, we must take actions that we anticipate will do the greatest good," she said. Speaking at a briefing on Friday, the CDC director said "our healthcare systems are once again at maximum capacity in parts of the country. "Our teachers are facing uncertainty as they walk into the classroom, and I must do what I can to preserve the health across our nation," she said. The CDC backed the expert panel's recommendation of booster shots for over-65s and some with underlying medical conditions. The decision came after the US Food and Drug Administration (FDA) approved Pfizer booster shots for a broader swathe of the American public. A day before the CDC recommendation, its expert committee had voted against offering booster shots to workers in the higher risk category, adding to confusion around the campaign. The hours-long debate left several experts torn, as the scientific community has so far failed to reach consensus on whether a coronavirus vaccine booster shot is necessary at this time. Some experts have concerns about the lack of data on the efficacy and safety of adding another shot to the Pfizer vaccine regimen. The original two doses are still proving successful at keeping the vast majority of their recipients out of the hospital with coronavirus, they say. But data does suggest that the vaccine's efficacy against infection does significantly decline in older people over time.

Newsletter

Get updates straight to your inbox

Popular Categories

In the Hood | Asia This Week | Singapore Politics | SG Economy | Relationships